Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Fluids Barriers CNS ; 18(1): 57, 2021 Dec 07.
Article in English | MEDLINE | ID: mdl-34876168

ABSTRACT

BACKGROUND: Little is known about the extent of drug entry into developing brain, when administered to pregnant and lactating women. Lithium is commonly prescribed for bipolar disorder. Here we studied transfer of lithium given to dams, into blood, brain and cerebrospinal fluid (CSF) in embryonic and postnatal animals as well as adults. METHODS: Lithium chloride in a clinically relevant dose (3.2 mg/kg body weight) was injected intraperitoneally into pregnant (E15-18) and lactating dams (birth-P16/17) or directly into postnatal pups (P0-P16/17). Acute treatment involved a single injection; long-term treatment involved twice daily injections for the duration of the experiment. Following terminal anaesthesia blood plasma, CSF and brains were collected. Lithium levels and brain distribution were measured using Laser Ablation Inductively Coupled Plasma-Mass Spectrometry and total lithium levels were confirmed by Inductively Coupled Plasma-Mass Spectrometry. RESULTS: Lithium was detected in blood, CSF and brain of all fetal and postnatal pups following lithium treatment of dams. Its concentration in pups' blood was consistently below that in maternal blood (30-35%) indicating significant protection by the placenta and breast tissue. However, much of the lithium that reached the fetus entered its brain. Levels of lithium in plasma fluctuated in different treatment groups but its concentration in CSF was stable at all ages, in agreement with known stable levels of endogenous ions in CSF. There was no significant increase of lithium transfer into CSF following application of Na+/K+ ATPase inhibitor (digoxin) in vivo, indicating that lithium transfer across choroid plexus epithelium is not likely to be via the Na+/K+ ATPase mechanism, at least early in development. Comparison with passive permeability markers suggested that in acute experiments lithium permeability was less than expected for diffusion but similar in long-term experiments at P2. CONCLUSIONS: Information obtained on the distribution of lithium in developing brain provides a basis for studying possible deleterious effects on brain development and behaviour in offspring of mothers undergoing lithium therapy.


Subject(s)
Antimanic Agents/pharmacokinetics , Blood , Brain , Cerebrospinal Fluid , Lithium Chloride/pharmacokinetics , Maternal-Fetal Exchange , Milk, Human , Animals , Animals, Newborn , Animals, Suckling , Antimanic Agents/administration & dosage , Antimanic Agents/blood , Antimanic Agents/cerebrospinal fluid , Choroid Plexus , Embryo, Mammalian , Female , Lactation , Lithium Chloride/administration & dosage , Lithium Chloride/blood , Lithium Chloride/cerebrospinal fluid , Pregnancy , Rats , Rats, Sprague-Dawley
2.
PLoS One ; 9(11): e113607, 2014.
Article in English | MEDLINE | ID: mdl-25409333

ABSTRACT

Pneumococcal meningitis is associated with high morbidity and mortality rates. Brain damage caused by this disease is characterized by apoptosis in the hippocampal dentate gyrus, a morphological correlate of learning deficits in experimental paradigms. The mood stabilizer lithium has previously been found to attenuate brain damage in ischemic and inflammatory diseases of the brain. An infant rat model of pneumococcal meningitis was used to investigate the neuroprotective and neuroregenerative potential of lithium. To assess an effect on the acute disease, LiCl was administered starting five days prior to intracisternal infection with live Streptococcus pneumoniae. Clinical parameters were recorded, cerebrospinal fluid (CSF) was sampled, and the animals were sacrificed 42 hours after infection to harvest the brain and serum. Cryosections of the brains were stained for Nissl substance to quantify brain injury. Hippocampal gene expression of Bcl-2, Bax, p53, and BDNF was analyzed. Lithium concentrations were measured in serum and CSF. The effect of chronic lithium treatment on spatial memory function and cell survival in the dentate gyrus was evaluated in a Morris water maze and by quantification of BrdU incorporation after LiCl treatment during 3 weeks following infection. In the hippocampus, LiCl significantly reduced apoptosis and gene expression of Bax and p53 while it increased expression of Bcl-2. IL-10, MCP-1, and TNF were significantly increased in animals treated with LiCl compared to NaCl. Chronic LiCl treatment improved spatial memory in infected animals. The mood stabilizer lithium may thus be a therapeutic alternative to attenuate neurofunctional deficits as a result of pneumococcal meningitis.


Subject(s)
Apoptosis/drug effects , Dentate Gyrus/metabolism , Lithium Chloride/pharmacology , Neuroprotective Agents/pharmacology , Spatial Memory/drug effects , Animals , Brain/pathology , Chemokine CCL2/cerebrospinal fluid , Dentate Gyrus/cytology , Dentate Gyrus/drug effects , Disease Models, Animal , Down-Regulation/drug effects , Interleukin-10/cerebrospinal fluid , Lithium Chloride/blood , Lithium Chloride/cerebrospinal fluid , Meningitis, Pneumococcal/drug therapy , Meningitis, Pneumococcal/metabolism , Meningitis, Pneumococcal/pathology , Microscopy, Fluorescence , Neuroprotective Agents/blood , Neuroprotective Agents/therapeutic use , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Streptococcus pneumoniae/pathogenicity , Tumor Necrosis Factor-alpha/cerebrospinal fluid , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Up-Regulation/drug effects , bcl-2-Associated X Protein/genetics , bcl-2-Associated X Protein/metabolism
3.
Biol Pharm Bull ; 36(11): 1829-34, 2013.
Article in English | MEDLINE | ID: mdl-24189427

ABSTRACT

To clarify whether peripheral inflammation has a remote effect on the central nervous system, the electrolyte disposition between the circulating blood and central nervous system was evaluated in rats with carrageenan-induced acute peripheral inflammation (API). λ-Carrageenan was subcutaneously injected in the hind paw of the rat, and lithium was utilized as a surrogate marker of sodium. When the plasma and cerebrospinal fluid (CSF) concentrations of lithium were examined following lithium being intravenously administered, it was revealed that the CSF concentration of lithium in API rats is reduced compared to that in normal rats, while the plasma concentration profile of lithium in API rats is indistinguishable from that in normal rats. The pharmacokinetic analysis showed that the lithium disposition from the plasma to CSF markedly decreased by 35.8% in API rats compared to that in normal rats. On the other hand, when lithium was immediately administered into the lateral ventricle, its elimination profiles in CSF were not different between normal and API rats. It is therefore probable that the lithium disposition from the plasma to CSF alters in API rats, reflecting the entry process of electrolytes from the circulating blood to brain tissue being suppressed in response to peripheral inflammation.


Subject(s)
Electrolytes/cerebrospinal fluid , Inflammation/metabolism , Lithium Chloride/pharmacokinetics , Animals , Carrageenan , Inflammation/chemically induced , Lithium Chloride/blood , Lithium Chloride/cerebrospinal fluid , Male , Orosomucoid/metabolism , Rats , Rats, Wistar
4.
Biopharm Drug Dispos ; 31(8-9): 455-63, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20848389

ABSTRACT

The altered electrolyte handling of the choroid plexus was investigated in rats with acute renal failure (ARF) using lithium and rubidium as surrogate markers for sodium and potassium, respectively. Firstly, the transport of these two markers from the plasma to cerebrospinal fluid (CSF) was evaluated after they were concurrently injected into the femoral vein. As a result, their disposition from the plasma to CSF was shown to decrease in ARF rats, but the relationship profile between those two markers was not different from that observed in normal rats, indicating that the decreased disposition of lithium and rubidium occurs without affecting the stoichiometric balance. To clarify the mechanisms accounting for the decreased disposition, an inhibition study was then performed. When bumetanide, an inhibitor of the Na(+) /K(+) /2Cl(-) co-transporter, was directly introduced into the cerebroventricle prior to lithium and rubidium being intravenously administered, a marked increase in the markers' disposition was observed. However, such an increased disposition did not occur when bumetanide was injected into the femoral vein. Other inhibitors, such as amiloride for the Na(+) /H(+) exchanger and ouabain for Na(+) /K(+) -ATPase, did not show any effects on marker disposition regardless of the inhibitor being administered into either the cerebroventricle or femoral vein. These findings suggest that the decreased marker disposition in ARF rats is due to an increased efflux process of the choroid plexus mediated by the Na(+) /K(+) /2Cl(-) co-transporter. That is, electrolyte efflux from the CSF to plasma increases, and thereby the electrolyte influx from the plasma to CSF is counteracted.


Subject(s)
Acute Kidney Injury/metabolism , Chlorides/metabolism , Choroid Plexus/metabolism , Electrolytes/metabolism , Lithium Chloride/metabolism , Rubidium/metabolism , Acute Kidney Injury/chemically induced , Animals , Area Under Curve , Bumetanide/pharmacology , Chlorides/blood , Chlorides/cerebrospinal fluid , Electrolytes/blood , Electrolytes/cerebrospinal fluid , Glycerol , Ion Transport , Lithium Chloride/blood , Lithium Chloride/cerebrospinal fluid , Male , Potassium/metabolism , Rats , Rats, Wistar , Rubidium/blood , Rubidium/cerebrospinal fluid , Sodium/metabolism , Sodium-Potassium-Chloride Symporters/metabolism , Solute Carrier Family 12, Member 2
5.
Pharm Res ; 25(10): 2243-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18581208

ABSTRACT

PURPOSE: The lithium disposition to cerebrospinal fluid (CSF) was evaluated in rats with acute renal failure (ARF) to examine whether electrolyte homeostasis of the CSF is perturbed by kidney dysfunction. In addition, the effects of renal failure on choroid plexial expressions of the Na+-K+-2Cl- co-transporter (NKCC1) and Na+/H+ exchanger (NHE1) were also studied. METHODS: After lithium was intravenously administered at a dose of 4 mmol/kg, its concentration profile in plasma was evaluated by collecting plasma specimens, while that in CSF was monitored with a microdialysis probe in the lateral ventricles. NKCC1 and NHE1 expressions were measured via the Western immunoblot method using membrane specimens prepared from the choroid plexus in normal and ARF rats. RESULTS: The lithium concentration in CSF of ARF rats was 30% lower than that of normal rats, while their plasma lithium profiles were almost the same, indicating that the lithium disposition to CSF was decreased in ARF rats. It was revealed that the choroid plexial expression of NKCC1 was increased by 40% in ARF rats, but that of NHE1 was unchanged. CONCLUSION: ARF decreases the lithium disposition to CSF, possibly by promoting lithium efflux from CSF due to increased NKCC1 expression in the choroid plexus.


Subject(s)
Acute Kidney Injury/metabolism , Lithium Chloride/pharmacokinetics , Water-Electrolyte Balance , Acute Kidney Injury/blood , Acute Kidney Injury/cerebrospinal fluid , Acute Kidney Injury/chemically induced , Animals , Choroid Plexus/metabolism , Disease Models, Animal , Glycerol , Injections, Intravenous , Lithium Chloride/administration & dosage , Lithium Chloride/blood , Lithium Chloride/cerebrospinal fluid , Male , Microdialysis , Rats , Rats, Wistar , Sodium-Hydrogen Exchanger 1 , Sodium-Hydrogen Exchangers/metabolism , Sodium-Potassium-Chloride Symporters/metabolism , Solute Carrier Family 12, Member 2
SELECTION OF CITATIONS
SEARCH DETAIL
...